Drug Trial Radar · NCT04929223
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
542
Planned (sponsor's estimate)
Start
Oct 22, 2021
Primary completion
Aug 31, 2030
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Conditions
- Metastatic Colorectal Cancer
Interventions
InavolisibDrug
Inavolisib will be administered orally as per schedule specified in the respective arms.
BevacizumabDrug
Bevacizumab IV will be administered as per schedule specified in the respective arm.
CetuximabDrug
Cetuximab IV will be administered as per schedule specified in the respective arm.
AtezolizumabDrug
Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
TiragolumabDrug
Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
SY-5609Drug
SY-5609 will be administered by mouth as per schedule specified in the respective arm.
DivarasibDrug
Divarasib will be administered orally as per schedule specified in the respective arms.
FOLFOXDrug
FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
FOLFIRIDrug
FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
FoundationOne®Liquid CDxDiagnostic test
FoundationOne®Liquid CDx is used to identify presence of genomic alterations for participant cohort assignment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Approximately 84 months
Locations
84 sites in 11 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama · Withdrawn
Mayo Clinic Arizona
Phoenix, Arizona · Active not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
cCare
Encinitas, California · Withdrawn
USC Norris Cancer Center
Los Angeles, California · Completed
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UCLA
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Withdrawn
Stanford Cancer Center
Stanford, California · Completed
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Eastern Ct Hema/Onco Assoc
Norwich, Connecticut · Withdrawn
Mayo Clinic in Florida
Jacksonville, Florida · Completed
Moffitt Cancer Center
Tampa, Florida · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Mary Bird Perkins Cancer Ctr
Baton Rouge, Louisiana · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Completed
Karmanos Cancer Institute
Detroit, Michigan · Withdrawn
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
New York Cancer & Blood Specialists - New Hyde Park
New Hyde Park, New York · Recruiting
New York Cancer and Blood Specialists-Central Park Hematology & Oncology
New York, New York · Recruiting
New York Cancer & Blood Specialists
Port Jefferson Station, New York · Recruiting
New York Cancer & Blood Specialists - Bronx
The Bronx, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Completed
Hematology Oncology Salem
Salem, Oregon · Completed
UPMC - Hillman Cancer Center
Pittsburgh, Pennsylvania · Active not recruiting
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee · Completed
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Completed
Texas Oncology - Northeast Texas
Denton, Texas · Recruiting
Lumi Research
Kingwood, Texas · Withdrawn
Texas Oncology - Gulf Coast
Webster, Texas · Recruiting
Swedish Cancer Inst.
Seattle, Washington · Completed
Medical Oncology Associates
Spokane, Washington · Withdrawn
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Active not recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Withdrawn
McGill University Health Center
Montreal, Quebec, Canada · Withdrawn
Herlev Hospital, Afdeling for Kræftbehandling, Center for Kræftforskning, Klinisk Forskningsenhed
Herlev, Denmark · Recruiting
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.